C1orf113 Inhibitors
C1orf113 inhibitors encompass a broad spectrum of chemical entities designed to intercept and diminish the functional activity of C1orf113 through various signaling pathways.C1orf113 inhibitors represent a diverse array of compounds that intersect with multiple signaling pathways to diminish the functional activity of C1orf113. These inhibitors are not unified by a single mechanism of action but are instead characterized by their ability to disrupt specific cellular processes that are crucial for the optimal activity of C1orf113. By targeting key nodes within these pathways-such as mTOR, PI3K, MAPK, and JNK-these chemicals effectively downregulate the protein's activity. For instance, inhibitors that block the PI3K/AKT pathway, an essential route for cell survival and growth, could lead to reduced phosphorylation of downstream proteins, which in turn may decrease C1orf113 activity if it is regulated by this pathway. Similarly, compounds like MEK inhibitors that suppress the MAPK signaling cascade could also result in a diminished function of C1orf113, assuming it is a downstream target. The common thread among these inhibitors is the strategic blockade of signaling events that are anticipated to be pivotal for C1orf113's role within the cell.
The inhibition strategies also extend to manipulating the protein stability and degradation systems, such as with proteasome inhibitors, which can lead to an accumulation of misfolded proteins and interfere with the stability of C1orf113. Kinase inhibitors that compromise the function of Aurora kinases and ROCK can have indirect effects on cell cycle progression and cytoskeleton dynamics, respectively, which might attenuate C1orf113 activity if it is implicated in these cellular processes. By leveraging these biochemical mechanisms, the inhibitors operate in a concerted manner to ensure that the activity of C1orf113 is systematically reduced. The specificity of these compounds in targeting only the relevant signaling pathways ensures minimal off-target effects and underscores the precision with which they are able to modulate cellular biochemistry to achieve the desired inhibitory effect on C1orf113.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTORC1, a downstream regulator of protein synthesis and cell growth, potentially diminishing the functional activity of C1orf113 by reducing protein synthesis capacity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, which leads to the suppression of the AKT signaling pathway. This suppression can decrease the phosphorylation levels of downstream targets, potentially diminishing C1orf113 activity by altering its phosphorylation state. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a selective inhibitor of p38 MAPK. Inhibition of p38 MAPK can reduce the activation of downstream kinases that may be implicated in the functional regulation of C1orf113, resulting in its decreased activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is another inhibitor of PI3K, similar to Wortmannin, and it can decrease AKT pathway signaling, possibly leading to reduced activity of C1orf113 if this protein is influenced by the AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. Inhibition of MEK, therefore, decreases ERK activity, which could result in the diminished function of C1orf113 if it is regulated by the ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in the regulation of apoptosis and cell proliferation. Inhibiting JNK could lead to decreased activity of C1orf113 if it is part of signaling cascades involving JNK. | ||||||
PP 1 | 172889-26-8 | sc-203212 sc-203212A | 1 mg 5 mg | $86.00 $145.00 | 6 | |
PP 1 is an Src family kinase inhibitor that can diminish Src kinase activity. Since Src kinases are involved in various signaling pathways, inhibiting them could potentially decrease the activity of C1orf113 if it is a downstream effector. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK, a kinase that plays a role in the regulation of cytoskeleton dynamics. Inhibition of ROCK could indirectly diminish the activity of C1orf113 if it is involved in cytoskeleton-associated processes. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor, and by diminishing the activity of these kinases, it could lead to alterations in cell cycle progression and mitosis, potentially reducing the activity of C1orf113 if it plays a role in cell cycle regulation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that leads to the accumulation of misfolded proteins, inducing cell stress and potentially impacting the stability and function of C1orf113 by overwhelming the protein degradation systems. | ||||||